Direct inhibition of thrombin may offer similar anticoagulant properties but also impact the underlying disease process. As we continue to gain experience and develop new DTIs, a new balance may ...

Intravenous administration only. Used for the treatment of HIT (heparin induced thrombocytopenia). Monitored by aPTT - goal is 1.5 to 3.0 times above baseline. Renally cleared. Not easily reversed ...

Summary: Ximelagatran is the first orally active direct thrombin inhibitor to be tested in Phase III clinical trials. After oral administration, ximelagatran is rapidly converted to its active ...

Whether thrombin generation is attenuated (by FXa inhibitors) or thrombin activity ... is a novel oral once-daily direct thrombin inhibitor that has recently been approved by the European ...